Breaking News

Cellular Origins Completes $40M Series A Round

The investment gives the company access to the capital and networks to drive its next phase of growth.

Author Image

By: Charlie Sternberg

Associate Editor

Cellular Origins, a company that enables the manufacturing of cell therapies at scale, has completed a $40 million over-subscribed Series A round led by Johnson & Johnson through its corporate venture capital organization, with additional support from Highland Europe, BGF, NYBC Ventures, and TTP Group. Cellular Origins removes barriers to scale by applying its proprietary robotic automation to connect individual third party unit operations already used in cell therapy processes. The resul...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters